Par Drugs Financials
| PAR Stock | 185.41 6.89 3.58% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Operating Income | 666 M | 634.3 M |
|
|
Par | Select Account or Indicator |
Please note, the presentation of Par Drugs' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Par Drugs' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Par Drugs' management manipulating its earnings.
Par Drugs Stock Summary
Par Drugs competes with Iris Clothings, G Tec, Indian Card, Gujarat Lease, and Can Fin. Par Drugs is entity of India. It is traded as Stock on NSE exchange.| Foreign Associate | USA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | India Stock View All |
| Exchange | National Stock Exchange of India |
| ISIN | INE04LG01015 |
| Business Address | 816, Nilamber Triumph, |
| Sector | Pharmaceuticals |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.pardrugs.com |
| Phone | 91 26 5299 1022 |
You should never invest in Par Drugs without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Par Stock, because this is throwing your money away. Analyzing the key information contained in Par Drugs' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Par Drugs Key Financial Ratios
There are many critical financial ratios that Par Drugs' investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Par Drugs And reports annually and quarterly.| Revenue | 956.4 M | ||||
| Gross Profit | 685.63 M | ||||
| EBITDA | 229.53 M | ||||
| Net Income | 145.01 M | ||||
| Total Asset | 1.02 B |
Par Drugs Key Balance Sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 763.8M | 786.9M | 888.7M | 1.0B | 1.2B | 763.9M | |
| Other Current Liab | 19.7M | 42.0M | 59.0M | 21.1M | 24.2M | 24.9M | |
| Net Debt | (128.4M) | (162.1M) | (222.4M) | (366.5M) | (329.9M) | (313.4M) | |
| Retained Earnings | 291.3M | 368.0M | 481.6M | 625.5M | 719.3M | 755.3M | |
| Accounts Payable | 67.2M | 106.6M | 80.9M | 53.6M | 61.6M | 75.1M | |
| Cash | 211.6M | 162.1M | 222.4M | 366.5M | 421.5M | 442.6M | |
| Other Assets | 7.1M | 7.6M | 7.6M | 7.3M | 8.4M | 5.1M | |
| Net Receivables | 126.2M | 217.4M | 218.2M | 137.1M | 157.7M | 140.6M | |
| Inventory | 30.0M | 47.1M | 53.8M | 44.2M | 39.8M | 34.4M | |
| Other Current Assets | 35.1M | 9.1M | (1K) | 47.4M | 54.5M | 57.2M | |
| Total Liab | 241.7M | 188.1M | 176.3M | 159.8M | 143.8M | 203.6M | |
| Total Current Assets | 411.9M | 435.6M | 494.4M | 596.2M | 685.7M | 720.0M | |
| Short Term Debt | 39.3M | 90K | 623K | (51K) | (45.9K) | (43.6K) | |
| Other Liab | 37.5M | 40.4M | 38.0M | 39.5M | 45.5M | 41.5M | |
| Net Tangible Assets | 290.3M | 406.1M | 522.1M | 598.8M | 688.6M | 433.3M | |
| Net Invested Capital | 598.5M | 598.8M | 712.4M | 856.3M | 984.8M | 631.7M | |
| Net Working Capital | 252.1M | 287.1M | 354.5M | 471.8M | 542.6M | 569.8M |
Par Drugs Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Revenue | 598.8M | 742.0M | 951.0M | 956.4M | 1.1B | 669.2M | |
| Gross Profit | 224.4M | 243.4M | 286.9M | 609.9M | 701.4M | 736.4M | |
| Operating Income | 131.9M | 129.7M | 149.7M | 551.6M | 634.3M | 666.0M | |
| Ebit | 153.7M | 129.7M | 149.7M | 195.2M | 224.4M | 235.7M | |
| Ebitda | 181.9M | 162.5M | 182.1M | 229.5M | 264.0M | 142.9M | |
| Cost Of Revenue | 374.4M | 498.6M | 664.0M | 346.5M | 398.5M | 413.1M | |
| Income Before Tax | 147.3M | 127.0M | 150.8M | 195.2M | 224.4M | 235.7M | |
| Net Income | 116.1M | 92.1M | 113.3M | 145.0M | 166.8M | 175.1M | |
| Income Tax Expense | 31.1M | 34.9M | 37.5M | 50.2M | 57.7M | 60.6M | |
| Interest Expense | 6.0M | 3.8M | 24K | 1.1M | 963.9K | 915.7K | |
| Tax Provision | 31.1M | 34.9M | 37.5M | 50.2M | 57.7M | 29.1M | |
| Net Interest Income | (6.4M) | (4.5M) | (613K) | (1.1M) | (1.2M) | (1.3M) | |
| Interest Income | 1.3M | 1.8M | 719K | 2.3M | 2.7M | 2.8M | |
| Research Development | 988K | 147.4K | 1.0M | 3.3M | 3.8M | 4.0M |
Par Drugs Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Par Drugs And. It measures of how well Par is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Par Drugs brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Par had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Par Drugs has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change To Inventory | (799.1K) | (17.2M) | (6.7M) | 12.0M | 13.8M | 14.5M | |
| Change In Cash | 137.8M | (49.6M) | 60.4M | 144.1M | 165.7M | 174.0M | |
| Free Cash Flow | 70.4M | 44.1M | 57.4M | 141.7M | 162.9M | 171.1M | |
| Depreciation | 28.2M | 32.8M | 32.3M | 34.4M | 39.5M | 33.2M | |
| Other Non Cash Items | (51.2M) | (29.4M) | (44.7M) | 3.1M | 2.8M | 2.9M | |
| Capital Expenditures | 50.5M | 32.0M | 76.3M | 60.8M | 69.9M | 73.4M | |
| Net Income | 147.3M | 127.0M | 150.8M | 145.0M | 166.8M | 88.5M | |
| End Period Cash Flow | 211.6M | 162.1M | 222.4M | 366.5M | 421.5M | 442.6M | |
| Net Borrowings | (73.3M) | (57.3M) | 30.2M | (76.4M) | (68.8M) | (65.3M) | |
| Change To Netincome | 13.5M | 10.2M | (20.1M) | 5.4M | 4.9M | 5.6M |
Par Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Par Drugs's current stock value. Our valuation model uses many indicators to compare Par Drugs value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Par Drugs competition to find correlations between indicators driving Par Drugs's intrinsic value. More Info.Par Drugs And is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers reporting about 0.66 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Par Drugs And is roughly 1.51 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Par Drugs' earnings, one of the primary drivers of an investment's value.Par Drugs And Systematic Risk
Par Drugs' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Par Drugs volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty with a total number of output elements of thirty-one. The Beta measures systematic risk based on how returns on Par Drugs And correlated with the market. If Beta is less than 0 Par Drugs generally moves in the opposite direction as compared to the market. If Par Drugs Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Par Drugs And is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Par Drugs is generally in the same direction as the market. If Beta > 1 Par Drugs moves generally in the same direction as, but more than the movement of the benchmark.
Par Drugs And Total Assets Over Time
Par Drugs Thematic Clasifications
Par Drugs And is part of Drugs investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Drug manufacturing and delivery. Companies involved in medical and pharmaceutical drug research, manufacturing, and delivery
This theme covers Drug manufacturing and delivery. Companies involved in medical and pharmaceutical drug research, manufacturing, and delivery. Get More Thematic Ideas
| Drugs | View |
Par Drugs January 30, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Par Drugs help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Par Drugs And. We use our internally-developed statistical techniques to arrive at the intrinsic value of Par Drugs And based on widely used predictive technical indicators. In general, we focus on analyzing Par Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Par Drugs's daily price indicators and compare them against related drivers.
| Information Ratio | (0.09) | |||
| Maximum Drawdown | 39.98 | |||
| Value At Risk | (5.46) | |||
| Potential Upside | 8.13 |
Complementary Tools for Par Stock analysis
When running Par Drugs' price analysis, check to measure Par Drugs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Par Drugs is operating at the current time. Most of Par Drugs' value examination focuses on studying past and present price action to predict the probability of Par Drugs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Par Drugs' price. Additionally, you may evaluate how the addition of Par Drugs to your portfolios can decrease your overall portfolio volatility.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |